Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.69 |
| ▸ | MAPT | P10636 | 4/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.63 |
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.63 |
| ▸ | HTT | P42858 | 3/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.52 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.52 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.52 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.52 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1922849 | 0.93 | MEN1 (0.61) | MEN1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL12156712 | 0.89 | KMT2A (0.90) | MEN1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL12156718 | 0.88 | TRPA1 (0.62) | MEN1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL1923159 | 0.87 | MEN1 (0.55) | MEN1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL12156713 | 0.86 | MEN1 (0.61) | MEN1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL1923059 | 0.84 | MEN1 (0.52) | MEN1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL1164525 | 0.83 | TRPA1 (0.54) | MEN1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL1923063 | 0.82 | TRPA1 (0.53) | MEN1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL1164665 | 0.82 | TRPA1 (0.53) | MEN1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL12156719 | 0.81 | SMN1; SMN2 (0.60) | MEN1KMT2AMAPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8049037-B2 | Sphingosine-1-phosphate (S1P) receptor antagonists and methods for use thereof | ALLERGAN, INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-8049037-B2 | Sphingosine-1-phosphate (S1P) receptor antagonists and methods for use thereof | ALLERGAN, INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-8049037-B2 | Sphingosine-1-phosphate (S1P) receptor antagonists and methods for use thereof | ALLERGAN, INC. (US) | 2011-11-01 | — | — | US | disclosed |
| EP-2328863-A1 | SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONISTS AND METHODS FOR USE THEREOF | Allergan, Inc. (US) | 2011-06-08 | — | — | EP | disclosed |
| WO-2010019646-A1 | SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONISTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041715-A1 | SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONISTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041715-A1 | SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONISTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041715-A1 | SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONISTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041715-A1 | SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONISTS AND METHODS FOR USE THEREOF | S1PR1, S1PR2, S1PR3 | MEN1 2283/4885KMT2A 2540/4885MAPT 4426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.